FY 2003 |
FY 2004 |
FY 2005 |
Increase |
|
---|---|---|---|---|
Program Level |
$471,065,000 |
$476,421,000 |
$521,808,000 |
+ $45,387,000 |
FTE |
3,942 |
3,965 |
3,994 |
+ 29 |
Budget Authority |
$456,148,000 |
$453,935,000 |
$502,219,000 |
+ $48,284,000 |
Foods |
$259,520,000 |
$265,959,000 |
$306,170,000 |
+ $40,211,000 |
Human Drugs |
$85,236,000 |
$82,400,000 |
$82,553,000 |
+ $153,000 |
Biologics |
$27,927,000 |
$26,299,000 |
$26,591,000 |
+ $292,000 |
Animal Drugs & Feed |
$30,544,000 |
$29,192,000 |
$35,814,000 |
+ $6,622,000 |
Medical Devices |
$52,921,000 |
$50,085,000 |
$51,091,000 |
+ $1,006,000 |
Budget Authority |
||||
Cost of Living - Pay 3/ |
$6,544,000 |
+ $6,544,000 |
||
Food Defense - CT |
$40,500,000 |
+ $40,500,000 |
||
Bovine Spongiform |
$6,675,000 |
+ $6,675,000 |
||
Medical Device Review |
$1,006,000 |
+ $1,006,000 |
||
Medical Countermeasures - CT |
$450,000 |
+ $450,000 |
||
Administrative Efficiencies |
- $6,891,000 |
- $6,891,000 |
||
FTE |
- 59 |
- 59 |
||
User Fees |
$14,917,000 |
$22,486,000 |
$19,589,000 |
- $2,897,000 |
PDUFA |
$5,629,000 |
$10,328,000 |
$7,134,000 |
- $3,194,000 |
FTE |
41 |
69 |
40 |
- 29 |
MDUFMA |
$449,000 |
$849,000 |
912,000 |
+ $63,000 |
FTE |
4 |
8 |
10 |
+ 2 |
MQSA |
$8,839,000 |
$11,309,000 |
$11,543,000 |
+ $234,000 |
FTE |
15 |
16 |
16 |
0 |
1/Contains
a Budget Authority rescission of 0.59 percent for a total of $2,694,000
for Field Activities. |
Fiscal Year |
Program Level |
Budget Authority |
User Fees |
Program Level FTE |
---|---|---|---|---|
2001 Actual |
$327,754,000 |
$309,715,000 |
$18,039,000 |
3,148 |
2002 Actual 4/ |
$448,031,000 |
$432,724,000 |
$15,307,000 |
3,493 |
2003 Actual |
$471,065,000 |
$456,148,000 |
$14,917,000 |
4,003 |
2004 Enacted |
$476,421,000 |
$453,935,000 |
$22,486,000 |
3,965 |
2005 Estimate |
$521,808,000 |
$502,219,000 |
$19,589,000 |
3,994 |
4/ Includes FDA's FY 2002 Appropriation and the Counterterrorism Supplemental. |
The Office of Regulatory Affairs (ORA) is the lead office for all FDA field activities. Each of FDA's five major program areas has a complementary field component responsible for supporting the Centers in compliance with FDA regulations. ORA accomplishes this through the inspection of regulated products and manufacturers, conducting sample analysis on regulated products, maintaining import data entry systems, and advising key officials on regulations and compliance-oriented matters that have an impact on policy development and execution, and long-range program goals.
The Field is staffed by about 4,000 people, over 90 percent of who work in five Regional Offices, 20 District Offices, 13 laboratories, and 130 Resident Posts. OCI personnel are located throughout the field organization in Field Offices, Resident Offices and Domiciles, which are located in 26 cities throughout the U.S. FDA maintains offices and staff in all states except Wyoming. Offices are also maintained in the District of Columbia, the U.S. Virgin Islands and Puerto Rico.
ORA's work involves conducting inspections, in support of the Agency's premarket activities for human and animal drugs, biological products and medical devices. In addition, foreign and domestic inspections of establishments can include bioresearch monitoring of clinical research; preapproval inspections and laboratory method validations needed for premarket application decisions; and, inspections of manufacturing facilities to determine if the factory is able to manufacture the product to the specifications stated in the application.
To complement these premarket activities, the largest portion of ORA's work involves conducting domestic and foreign postmarket inspections of foods, human drugs, biologic, animal drug and feed, and medical device manufacturers to assess their compliance with Good Manufacturing Practice and biennial inspection requirements. ORA also monitors and samples imports to ensure the safety of the food supply and medical products.
In addition to overseeing regulated products on a surveillance or "for cause" basis when a problem is encountered, ORA staff also responds to emergencies and investigates incidents of product tampering and terrorist events or natural disasters that may impact FDA regulated goods.
To complement the regular field force, the Office of Criminal Investigations (OCI) investigates instances of criminal activity in FDA-regulated industries.
FDA Strategic Goal | FY 2005 Increase | What the Increase Buys | Related Performance Goal(s) |
---|---|---|---|
Strong FDA
Efficient Risk Management: The Most Public Health Bang for Our Regulatory Buck |
Cost of Living Pay -- +$6,544,000
Medical Device Review -- + $1,006,000 |
|
|
User Fees: +$297,000 MDUFMA--+$63,000
|
|
|
|
Improving Patient and Consumer Safety
Protecting America From Terrorism |
Bovine Spongiform Encephalopathy Food Defense - CT +$40,500,000 |
|
|
Protecting America From Terrorism | Medical Countermeasures - CT +$450,000 |
|
|
Food Registration and Prior NoticeFDA's registration system, one of the key provisions of the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (the Bioterrorism Act), is part of an interim final rule announced October 9 and published on October 10 that requires domestic and foreign food facilities to register with the agency by December 12, 2003. As a result, FDA will have, for the first time, an official roster of foreign and domestic food facilities, allowing timely notification and response in the event of a food safety threat. In addition to the registration rule, FDA published a second interim final regulation to enhance the safety and security of the food supply. This rule requires that FDA be provided advance notice of shipments of human and animal food being imported or offered for import into the U. S., effective December 12, 2003. In arriving at the interim rule, the FDA worked closely with the Bureau of Customs and Border Protection to ensure the new regulation promotes a coordinated strategy for border protection. FDA developed a new electronic registration system for food facilities, foreign and domestic. Each firm registering online will instantly receive its unique registration number, which will be required for doing business in the U.S. beginning December 12, 2003. In addition, FDA developed a web-based Prior Notice system to facilitate and streamline access by importers, domestic and international users of the system. |
FDA's request for pay cost increases is essential to accomplishing its mission .Without a specially trained national cadre of scientific staff, FDA's ability to adequately carry out the mission of protecting public health and providing consumer safety will be compromised. FDA must maintain staffing levels and scientific capabilities that meet the demands of an increasing workload and new challenges .Payroll costs, which account for over 60 percent of our total budget, significantly impact all FDA activities.
The total Agency request for pay increases is $14,352,000.The field activities portion of this increase is $6,544,000.Without this, the FDA's ability to fulfill its mission to protect the public health by helping safe and effective products reach the market in a timely way, and monitoring products for continued safety after they are in use, will be significantly reduced.
FDA must uphold its responsibility for ensuring the safety of approximately 80 percent of the nation’s food supply. The total Agency request for Food Defense is $65,000,000 and 109 FTE. The Field’s portion of this increase is $40,500,000 and 80 FTE. The possibility of food products being used as a vehicle for attack is particularly worrisome because such an event potentially affects everyone in the U.S. FDA must have the capability to assess and then reduce risks associated with unexpected and potentially widespread health and safety threats. Resources would allow the FDA to invest in the protection of citizens by:
Operation Liberty Shield:FDA Food Security Enhancements in Times of Heightened AlertIn March 2003, Operation Liberty Shield was launched to increase security and readiness in the U. S. at a time of elevated risk for a terrorist attack. This comprehensive national plan of action to protect many of America's critical infrastructures was a unified operation coordinated by the Department of Homeland Security that integrated selected national protective measures with the involvement and support of federal, state, local, and private responders and authorities from around the country. A key component of Operation Liberty< Shield was increasing and targeting surveillance of both domestic and imported food.The Field contributed to the initiative by conducting increased examinations of specific imported commodities based on FDA's risk/threat assessments; enhancing the import communities' awareness of food security at ports; conducting over eight hundred inspections of firms located in the U. S. based on risk/threat assessments with a focus on enhancing awareness of food security at these facilities; monitoring of imported foods (nearly 400 samples of imported foods were analyzed for chemical and microbiological contaminants; and, conducting domestic and import reconciliation exams to confirm that regulated commodities were what they purported to be, expose unexplained differences between associated documentation and the product, and uncover signs of tampering or counterfeiting. |
BSE or "Mad Cow Disease" is a deadly chronic, degenerative disorder affecting the central nervous system. Feed containing remnants of the slaughtering process, such as the brain and spinal cord, may harbor the agent that causes BSE. To ensure such substances are not contained in animal feed, and to prevent the establishment and spread of BSE through animal feed, the FDA finalized a regulation on August 4, 1997 entitled "Animal Proteins Prohibited from Use in Animal Feed". Since 1997, the main focus of our BSE-prevention program has been regular inspections of all renderers and feed mills in the U.S. With the additional resources, FDA will:
The requested increase will provide the resources needed to allow FDA to reach the required appropriation level for FY 2005 under the MDUFMA Act. The total Agency request for Medical Device Review is $25,555,000 and 50 FTE. The Field Activities program portion of this increase is $1,006,000 and 7 FTE.This increase in budget authority, coupled with the user fee funds for the review of medical device applications, will enable FDA to meet the aggressive premarket performance goals committed to under the legislation.This involves expediting review times which will support our agency wide initiative to make innovative medical technologies available to the public sooner, and helping to reduce the costs of developing safe and effective medical products while maintaining FDA's high standards of consumer protection. The additional funds will be used by FDA to:
FDA, working together with sister agencies such as CDC and NIH as well as DOD, and interacting with industry, health care providers and consumers, is at the forefront of the public health response related to countering terrorism and must have sufficient resources (potentially employing all types of assets such as full time and contract employees and partnerships with contracting and academic organizations) to continue to effectively and innovatively respond to the increasing and intensive level of activity required. The total Agency request for Medical Counter Measures is $5,000,000. The Field Activities program portion of this increase is $450,000, which will allow FDA to expand surveillance on emerging pathogens and strengthen the infrastructure among local, state, and federal public health providers to support prevention, surveillance, and control programs.
To fully embrace the President’s Management Agenda, FDA is delayering its organizational structure, performing competitive sourcing reviews, modernizing its financial management system, and consolidating its information technology infrastructure. The Field Activities portion of these management improvements consists of - $6,891,000 and - 59 FTE from the Agency-wide 198 FTE (7.5%) administrative efficiencies.
PDUFA authorized the FDA to collect fees from the pharmaceutical industry to augment appropriations spent on drug review. These additional resources were to be used to hire and support additional staff for the review of human drugs so that safe and effective drug products reach the American public more quickly. The Bioterrorism Act of 2002 reauthorized the collection of user fees to enhance the review process of new human drugs and biological products and established fees for applications, establishments, and approved products. The PDUFA amendments are effective for five years and direct FDA to strengthen and improve the review and monitoring of drug safety; consider greater interaction with sponsors during the review of drugs and biologics intended to treat serious diseases and life-threatening diseases; and, develop principles for improving first-cycle reviews.
Sound, risk-based review processes are imperative to ensure that medical devices on the market are safe and effective.To strengthen and expedite FDA’s medical device review process MDUFMA, was reauthorized in FY 2002 as multi-year effort to improve the quality and timeliness of the medical device review process through the use of user fees collected from those who submit premarket applications, certain supplements to those applications, and premarket notifications. These fees, which supplement appropriations for the medical device review program, will allow FDA to continue the following efforts:
Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths among American women. Experts estimate that one in eight American women will contract breast cancer during their lifetime. The MQSA was signed into law in 1992 to address the public health need for safe and reliable mammography. The Act required that mammography facilities be certified by October 1994 to be able to remain in operation, and inspected annually to ensure compliance with national quality and safety standards. The MQSA Program certifies mammography facilities and performs annual inspections to ensure that women have access to safe and effective mammography services. MQSA was not reauthorized by the 107th Congress because of concerns about the need to improve the skills of physicians reading mammogram's and the need for interpretive skills assessment to be added to existing MQSA continuing medical education requirements. The FDA has been working with Congressional staff to address these concerns and reauthorization of MQSA is expected in the current Congressional session. The fees collected pay for the costs of the annual inspections to ensure compliance with national quality standards. The increase of $234,000 will cover inflation.
Base resources will be used to conduct science-based risk management in all agency regulatory activities, so that limited resources can provide the most health promotion and protection at the least cost for the public. These activities will support:
Since the emergence of the "global marketplace" in the last 20 years, imported foods have grown to constitute more than 10 percent of the U.S. food supply. FDA data show that the number of imported food lines has doubled over the past seven years. This explosion in the number of imported food lines combined with the security concerns raised by terrorism and counterfeiting incidents has increased the need to physically assess the status of imported products as part of the Agency's emerging import strategy.
Inspections and surveillance are the primary means of assuring the safety of marketed products. Consumers rely on the FDA to prevent dangerous and unreliable products from entering commerce.
Base resources will be used to better enable consumers to make informed decisions weighing benefits and risks of FDA-regulated products. These activities include:
The Consumer Health Information for Better Nutrition (CHIBN) initiative is designed to foster two complementary goals concerning the labeling of food and dietary supplements: to encourage makers of conventional foods and dietary supplements to make accurate, science-based claims about the health benefits of their products, and to help to eliminate bogus labeling claims by taking on those dietary supplement marketers who make false or misleading claims.
EphedraIn February of 2003, FDA issued an Ephedra White Paper entitled, "Evidence on the Safety and Effectiveness of Ephedra: Implications for Regulation." FDA identified over 50 web sites that were promoting ephedrine-containing dietary supplements with unsubstantiated claims for athletic performance enhancement. Twenty-six Warning Letters were issued to firms making such claims, which< led to the companies' decision to remove their violative claims and to comply with the Act. FDA is continuing to monitor the companies' compliance and to the extent that additional enforcement steps are necessary to achieve compliance, we are prepared to take them. In December of 2003, FDA issued a consumer alert alerting the public to its forthcoming determination that dietary supplements containing ephedra present an unreasonable risk of illness or injury, and should not be consumed. The agency also notified 62 firms manufacturing and marketing dietary supplements containing ephedra and ephedrine alkaloids that it intends to issue a final rule prohibiting their sale, which will become effective 60 days after its publication. |
Recall Enterprise System (RES): The implementation of RES will provide the District and Centers with a centralized, Agency-wide recall database. RES will also provide the public with access to timely recall information via the FDA web site, and include information that provides detailed guidance for industry regarding developing and providing the District with background recall information.
FDA believes that roughly half of the deaths and injuries associated with medical errors can be avoided by fully implementing its strategies. Thousands of lives and billions of dollars can be saved.
Vigilance must be maintained in the generic drugs area. It is critical to ensure that the generic drug is identical to, or bioequivalent to a brand name drug in all critical respects.
To speed the availability of new products to consumers and to the market, the FDA must continue to focus on developing mechanisms to effectively and efficiently complete the review process.
FDA works closely with the USDA and state agricultural and veterinary agencies on implementation of BSE regulations and controlling imported products. FDA regulates many products that could contain specified risk materials, including vaccines, cosmetics, animal drugs, and animal feeds, and has established a comprehensive monitoring system to identify products that may pose a health risk and ensure that they do not enter the U.S.
Bovine Spongiform Encephalopathy (BSE)The main focus of the FDA's BSE-prevention program has been regular inspections of all renderers and feed mills in the U.S. More than 99 percent have achieved compliance with a 1997 FDA rule that prohibits the inclusion of most animal protein in feeds for cattle and other ruminants. The effectiveness of FDA's surveillance was most recently confirmed by the fact that all of the firms involved in the current Washington BSE investigation were found to be in compliance with the FDA rule, and that the agency working with State and industry was able to halt the distribution of all the meat and bone meal from the sick cow. |
At present, there are an exploding number of new web sites marketing FDA regulated products to the American consumer and medical professionals. FDA currently conducts only minimal levels of web-based oversight.
Base resources will be used to strengthen FDA’s capability to identify, prepare for, and respond to terrorist’s threats and incidents.
FDA must have the capacity to quickly and accurately identify and respond to potential terrorist events occurring at any point in the food chain, or in the distribution chain of other FDA regulated products and take prompt action to mitigate their effects. In the event of an identified threat, FDA will work with other Federal, state, and local agencies to eliminate or contain the hazard, reduce public health risk, and identify those who perpetrated the attack.
Base resources will be used to pursue this strategic goal of ensuring a world-class professional work force, effective and efficient operations and adequate resources to accomplish the mission of FDA. With these resources, FDA will continue to utilize ORA-wide Quality Management System (QMS) to enhance the current approach to managing quality work processes and products. It relies on clear, uniform, and accessible criteria for work processes, for quality control, and for feedback and system improvement. The QMS focuses on the managers’ responsibility to manage quality-related systems and is based on internationally accepted quality system standards.
Operation Liberty Shield: FDA participated in the federal government's nation-wide "Operation Liberty Shield" assignment from March 19 - April 16, 2003. The assignment included domestic inspections of food and cosmetics firms; sampling of targeted food and cosmetic commodities based on risk/threat assessments; import examinations; and domestic and import reconciliation examinations. Reconciliation exams were conducted to ensure that the targeted food/cosmetic was what it was purported to be; there were no unexplained differences in the quantity of products ordered and what was subsequently received; that there were no visible signs of tampering; and, that sampled products were not adulterated with contaminants of concern. In addition, during each domestic inspection or import examination, FDA issued the agency's "Security Preventive Measures Guidance Documents". Even though the domestic part of the operation ceased on April 16th, FDA continued to perform the import functions with heightened vigilance.
FDA/Customs Import Blitz Exams: FDA and Customs and Border Protection (CBP) personnel collaborated to conduct a series of import blitz exams on mail shipments of foreign drugs intended for U.S. consumers. The exams, conducted at the at the international mail facilities in Miami, New York (JFK airport), San Francisco, and Carson City (Los Angeles) in July and August, 2003 revealed that these shipments often contained dangerous, unapproved drugs that pose serious safety concerns. In addition, FDA conducted its import entry studies in Detroit and Buffalo as part of its efforts to combat illegally imported drugs.
Electronic Laboratory Exchange Network (eLEXNET): Continued the development and expansion of eLEXNET, the nation's first seamless data exchange system for food safety testing information. At present, there are 101 laboratories representing 50 states that are part of the eLEXNET system, 55 of which are actively submitting data into this system. Additionally, the United States, Canada and Mexico have agreed to establish a trilateral eLEXNET pilot to assess the utilities of this data sharing laboratory network among food laboratories in Mexico and Canada. We are continuing to increase the number of participating laboratories.
FERN (Food Emergency Response Network): Jointly, FDA is working with USDA to develop appropriate mechanisms to enhance the capacity/capabilities of the FERN. To this end, a Steering Committee has been developed to provide the initial infrastructure for FERN. Training has been offered to 100 employees from both FDA and States. Several FERN committees have joined to insert a proficiency program to assure that training is ample and analysts are competent at performing the analyses once trained in the classroom.
Import Prior Notice: FDA and Customs and Border Protection (CBP) collaborated on the development of, and subsequently signed, a MOU allowing FDA to commission thousands of CBP officers in ports and other locations to conduct, on FDA's behalf, investigations and examinations of imported foods. This unprecedented agreement significantly strengthened the implementation of the Bioterrorism Act in general, and the Prior Notice provisions specifically, to assure the security of imported foods. FDA developed a web-based Prior Notice system to facilitate and streamline access by importers, domestic and international users of the system.
Bioterrorism Outreach: FDA sponsored two world-wide public meetings via satellite downlink to explain the proposed Bioterrorism Regulations. The broadcasts were made available in English, Spanish and French and were shown at numerous sites across the nation, in addition to viewing sites in Canada, Mexico and South America. FDA also participated in over 80 domestic and international meetings with private trade groups and associations to explain the provisions of the regulations.
Mobile Laboratories: Featherlite, Inc. of Cresco, Iowa was awarded the contract to build two mobile analytical laboratories in September of 2003. These laboratories will provide flexible analytical capability that can be relocated easily to sites generating samples.
Hazardous Sample Collection Team: Developed and implemented a process and procedure for the collection of hazardous samples, including the creation of a team of "second responders," who will collect samples of FDA-regulated products if associated with a terrorist or tampering event. Identified, secured, and completed the appropriate training and equipment needs for this team.The Agency presently has two secondary responder teams that are certified and trained in hazardous material identification, protective equipment, DOT shipping requirements, and applicable regulations.
Medically Necessary Products for Defense: Worked closely with the Department of Defense (DOD) to assure that medically necessary products, e.g., Cyanide Antidote Treatment kits needed for the war in Iraq and domestic counter terrorism activities are available. FDA assisted DOD on a multi-million dollar contract for the purchase of two anti-malaria drugs and arranged with Chicago District Office for an emergency warehouse inspection to assess storage conditions.
Established an Emergency Communications Network: Established a backup Communications network to function in the event that "land-line phones" become compromised in an emergency and to augment existing communication channels. Cell phones and wireless e-mail communication devices that will be available in the event of an emergency on a separate cellular network, have been provided to the critical staff within FDA. We continue to augment this network and have utilized it during the emergency response exercises.
Radiation Safety: Implemented a "radiation pager program" for our import personnel to assure that import entries with radioactive material do not go undetected and to protect our employees.
Food Security Outreach to Industry: FDA and state officials continue to issue Food and Cosmetics Security Preventive Measures Guidance documents that recommend the types of preventive measures that companies can consider reducing the risk that products under their control will be subject to tampering, criminal or terrorist actions. FDA and state officials also discuss security awareness with each facility's management.
Bioterrorism Regulation Development: ORA heavily participated in writing the final regulations for Prior Notice, Facility Registration, Administrative Detention of food and Record keeping requirements needed to implement the Bioterrorism Act published in December 2003.
Bovine Spongiform Encephalopathy (BSE) Incident in Canada/Traceback on Pet Food: When Canada identified its first case of BSE, FDA and other Federal agencies included Canadian imports on the list of products that posed risks of transmission of BSE. Moreover, when the FDA learned from the government of Canada that rendered material from a Canadian cow that tested positive for BSE may have been used to manufacture pet food, some of which was shipped to the United States, FDA notified and worked with the U.S. distributor of the pet food firm to successfully recover the product before it was consumed.
BSE Injunction: A Consent Decree of Permanent Injunction was entered into with X-Cel Feeds, Inc., Takoma, WA, and individual officers of the corporation. The Consent Decree requires strict compliance with requirements designed to prevent potential contamination of ruminant animal feeds with prohibited mammalian proteins. This was the first injunction taken for violations of the 1997 regulation entitled, "Animal Protein Prohibited from Use in Ruminant Feed" that was issued to prevent the spread of BSE.
FDA Coordinates with States on BSE: FDA continues to leverage with state agencies by conducting training on the BSE feed regulation, establishing partnership agreements and funding contract inspections of feed mills, renderers, and others subject to the regulation, as well as conducting compliance and audit inspections. Through these efforts, FDA, along with State agricultural and veterinary agencies, has obtained a greater than 97 percent compliance rate with the BSE feed control regulations. The field met its FY 2003 performance goals by conducting inspections of 100 percent of the 880 firm inventories of renderers, protein blenders, and feed mills manufacturing or processing products using prohibited materials.
Ephedra-Containing Dietary Supplements: FDA issued an Ephedra White Paper entitled, "Evidence on the Safety and Effectiveness of Ephedra: Implications for Regulation." FDA identified over 50 web sites that were promoting ephedrine-containing dietary supplements with unsubstantiated claims for athletic performance enhancement. Twenty-six Warning Letters were issued to firms making such claims.
Internet Storefront Drugs from Canada: FDA issued a warning letter to one storefront operation facilitating the Internet sale and importation of unapproved prescription drugs from Canada. FDA also coordinated regulatory activities with state regulatory bodies and national regulatory organizations against storefront operations that import unapproved prescription drugs from Canada.
SARS Internet Claims: On May 9, 2003, FDA and FTC warned Web site operators, manufacturers and distributors to remove misleading or deceptive internet claims that their products may prevent, treat or cure Severe Acute Respiratory Syndrome (SARS). FDA sent Warning Letters to eight firms promoting dietary supplement products to treat or prevent SARS on the Internet.
American Red Cross Injunction: Since 1993, the American Red Cross (ARC) has been operating under a Consent Decree of Permanent Injunction due to inadequate controls it had in place for its blood collection and distribution activities. Following continued failure of ARC to come into full compliance with requirements, the Consent Decree was amended on April 15, 2003, to add monetary penalties for failing to comply with the decree requirements. When continued non-compliance was found, FDA followed procedures to impose monetary penalties.
Radiation Therapy Device Injunction: A Consent Decree of Permanent Injunction was entered into with Multidata Systems International Corp. and responsible individuals to enjoin this company from committing continued violations of medical device current good manufacturing practice and design standards involving this firm’s manufacture of radiation therapy devices. Previous failure of this firm to comply with such requirements had contributed to 28 patients receiving excessive amounts of radiation at a medical facility in Panama, with several deaths.
Interstate Sales of Diluted Cancer Drugs: On December 5, 2002, in Kansas City, MO, a Federal judge citing Robert Courtney's gross indifference to patient safety and welfare sentenced Courtney to 30 years confinement and ordered him to pay $10,452,109.67 in victim's restitution. Courtney pled guilty to 20 counts of Drug Tampering and FD&C Act violations. Courtney was a pharmacist who diluted cancer drugs prior to filling prescriptions from doctors and clinics.
Internet Drug Sale Enforcement Actions: FDA brought enforcement actions against several individuals selling prescription drugs without a doctor's prescription, individuals making fraudulent claims that their drug could cure cancer, and individuals selling unapproved drugs. These actions resulted in prison sentencing of over 18 years. FDA also issued eight Warning Letters to firms marketing alternatives to street drugs such as "ecstasy" on their web sites, and charged that these products are unapproved new drugs.
FDA/FTC Dietary Supplement Workgroup and Seizures: In coordination with the Federal Trade Commission (FTC) and as part of "Operation Cure All", FDA initiated seizure actions against two products marketed as dietary supplements which made false and unsubstantiated claims alleging that they could treat or cure serious diseases including cancer, multiple sclerosis, lupus, heart disease, and diabetes, among others. In June 2003, FDA initiated three separate seizures of Coral Calcium Supreme and Seasilver products with a combined value of $9.6 million.
Interstate Sales of Counterfeit Drugs: FDA brought criminal action against individuals selling counterfeit drugs and prescription drugs without a wholesaler license. These actions resulted in combined prison time of over 20 years and forfeiture of over $200,000 in assets.
Criminal Indictment in Warehouse Case: A five-count indictment was announced June 18, 2003, by the U.S. Attorney in the Northern District of Chicago, Illinois, charging three executives of LaGrou Distribution System, Inc., which operates cold storage food warehouses in the Chicago area, with storing more than 22 million pounds of adulterated meat, poultry, and other food products in unsanitary, rodent-infested conditions, and criminal conspiracy to violate federal public health standards. This enforcement action was in addition to a 2002 seizure of approximately $10,000,000 of FDA and USDA-regulated foods stored under unsanitary conditions.
Chloramphenicol in Food Seizures: FDA initiated seizures of foods contaminated with low levels of chloramphenicol, a potentially harmful antibiotic and unapproved food additive. Separate investigations revealed that imports of some bulk Chinese honey and certain imported seafood products were contaminated. This led to the seizures at three honey distributors, three crabmeat dealers, and one shrimp salad distributor.
Monkeypox Outbreak: FDA coordinated the activities of Federal, state and local agencies to respond to the introduction of the Monkeypox virus into the U. S. Together these agencies directly contacted over 4,400 facilities to inform them of the order banning the sale, distribution, transport or release into the environment of prairie dogs and six African rodent species. FDA is also continuing to implement the import embargo of rodents originating from Africa and the ban on bushmeat and the importation of trophy animals.
Contracts with the States: Increased the spending level of food contracts with the states from $4.2 million to $5.5 million which includes $1.1 million for medicated feeds; $850,000 for tissue residues; and, $135,000 for the Milk Residue Database.
State Collaboration: FDA has routine communication with its state contractors. FDA managed the electronic state Access to FACTS (eSAF) project. This new feature of the data system will allow state personnel to utilize the FACTS database to enter contract inspection data so that FDA will have more accurate and timely information on the compliance status of state monitored firms. Small Conference Grants were awarded in the amount of $102,600 to 21 states to support their annual State Food Safety Task Force Meetings.
International Cooperation: Devised and implemented procedures for FDA District Offices to share non-public information with the European Community auditors during their audits of FDA inspections. ORA held discussions with Korea, Israel, and Canada regarding their requests to develop Memoranda of Understanding (MOU) on Good Laboratory Practices. FDA's international cooperative agreements with other Organizations of Economic and Cooperative Development member countries resulted in the other member countries conducting eleven non-clinical laboratory safety study audits in Germany, Spain, UK, and Switzerland. FDA co-chaired an International Interagency Health Fraud Steering Committee working on developing consensus programs geared toward a common goal of fighting health fraud nationally and internationally.
Field Performance Goals: The field met or exceeded all twelve of its Performance Goals, which included but were not limited to: 78,659 import food field exams; 7,363 inspections of domestic high risk food establishments; 1,594 inspections of registered domestic blood banks, source plasma operations, and biologics manufacturing establishments; 584 inspections of registered high risk drug firms; 847 inspections of the registered domestic animal drug and feed establishments; 1,428 inspections of registered domestic Class II and Class III medical device manufacturers; 225 inspections of registered foreign Class II and Class III medical device manufacturers; and, 364 medical device bioresearch monitoring inspections.
Foreign Inspection Activities: A "model inspection process" was designed for conducting inspections in countries with an associated State Department Warning and Advisory. The model includes added security, transportation, and coordination with the local U.S. Embassy in an effort to accomplish mission critical work without compromising the safety of FDA investigators. This model has been used on numerous foreign inspection trips and has proven to be an effective tool to assure that the Agency can accomplish high priority work under secure conditions.
Laboratory Accreditation: Revisions to the laboratory quality manual and laboratory procedures manuals were completed. An accreditation audit was conducted at the Denver District Laboratory, resulting in the accreditation of this laboratory under ISO 17025, the first such successful accreditation in ORA. Other labs will undergo the accreditation process beginning in early FY 2004.
Rapid Methods / Test Kits: A contract was renewed with New Mexico State University to evaluate test kits to determine their suitability in FDA regulatory labs. Evaluation of five rapid test kits, designed for detection of E. coli/coliforms including E. coli 0175:H7 and Staphylococcus in various food matrices was completed. Currently, evaluations of test methods for Listeria and Shigella species are underway.
OASIS Import Data System: Enhanced the Operation and Administration Support Information System (OASIS) to include new priority exams and sample screening; filer evaluation history; and improvements to the Screening Criteria Management Form. This permits entry reviewers to better target products of risk.
PROGRAM OUTPUTS- |
FY 2003 |
FY 2004 |
FY 2005 |
---|---|---|---|
Domestic Food Safety Program Inspections |
7,218 |
7,000 |
7,750 |
Imported and Domestic Cheese Program Inspections |
523 |
800 |
800 |
Domestic Low Acid Canned Foods/ Acidified Foods Inspections |
623 |
600 |
600 |
Domestic Fish & Fishery Products (HACCP) Inspections |
2,561 |
3,700 |
3,700 |
Import (Imported Seafood Program Including HAACP) Inspections |
702 |
700 |
700 |
Juice HACCP Inspection Program (HACCP) |
311 |
200 |
200 |
Interstate Travel Sanitation (ITS) Inspections |
1,629 |
1,900 |
1,900 |
State Contract Food Safety ( Non HACCP) Inspections |
5,909 |
7,177 |
7,177 |
State Contract Domestic Seafood HACCP Inspections |
902 |
986 |
986 |
State Partnership Inspections |
1,579 |
2,000 |
2,000 |
Total FDA and State Contract Inspections |
21,957 |
25,063 |
25,813 |
State Contract and Grant Foods Funding |
$4,600,000 |
$9,600,000 |
$32,600,000 |
An estimated $28 million will be provided to the states for the Food Emergency Response Network; it will include $23 million in new funds for FY 2005 and $5 million in recurring funds from the FY 2004 appropriation. |
|||
Domestic Field Exams/Tests |
9,748 |
5,385 |
5,385 |
Domestic Laboratory Samples Analyzed |
14,505 |
17,000 |
17,000 |
PROGRAM OUTPUTS- |
FY 2003 |
FY 2004 |
FY 2005 |
---|---|---|---|
All Foreign Inspections |
145 |
255 |
255 |
Import Field Exams/Tests |
78,659 |
60,000 |
97,000 |
Import Laboratory Samples Analyzed |
25,736 |
31,700 |
32,000 |
104,395 |
91,700 |
129,000 |
|
In the spring of 2003, Operation Liberty Shield a one-time multi-department, multi-agency national plan resulted in increased protections for America's citizens and infrastructure.By leveraging its resources with partners, FDA increased surveillance of domestic and imported foods and enhanced collaboration with state and other government agencies. FY 2003 Food Import Field Exams increased due to unanticipated activities that were the result of this one-time initiative. |
|||
Import Line Decisions |
5,975,567 |
7,100,000 |
8,300,000 |
Percent Physical Exams Import Lines |
1.75% |
1.29% |
1.55% |
PROGRAM OUTPUTS- |
FY 2003 |
FY 2004 |
FY 2005 |
---|---|---|---|
All Inspections |
142 |
100 |
100 |
Domestic Field Exams/Tests |
519 |
75 |
75 |
PROGRAM OUTPUTS- |
|||
IMPORT/FOREIGN INSPECTIONS |
|||
Import Field Exams/Tests |
2,894 |
700 |
700 |
Import Laboratory Samples Analyzed |
254 |
100 |
100 |
Import Physical Exam Subtotal |
3,148 |
800 |
800 |
Import Lines |
753,809 |
900,000 |
1,000,000 |
Percent Physical Exams of Import Lines |
0.42% |
0.09% |
0.08% |
PROGRAM OUTPUTS- |
FY 2003 |
FY 2004 |
FY 2005 |
---|---|---|---|
Preapproval Inspections (NDA) |
168 |
140 |
140 |
Preapproval Inspections (ANDA) |
79 |
190 |
190 |
Bioresearch Monitoring Program Inspections |
687 |
612 |
612 |
Drug Processing (GMP) Program Inspections |
1,149 |
1,536 |
1,536 |
Compressed Medical Gas Manufacturers Inspections |
296 |
152 |
152 |
Adverse Drug Events Project Inspections |
72 |
100 |
100 |
OTC Monograph Project Inspections |
7 |
50 |
50 |
Health Fraud Project Inspections |
47 |
50 |
50 |
State Partnership: Compressed Medical Gas Manufacturers Inspections |
97 |
120 |
120 |
Total FDA and State Partnership Inspections |
2,602 |
2,950 |
2,950 |
Domestic Field Exams/Tests |
233 |
600 |
600 |
Domestic Laboratory Samples Analyzed |
1,925 |
1,328 |
1,328 |
PROGRAM OUTPUTS- |
|||
IMPORT/FOREIGN INSPECTIONS |
|||
Foreign Preapproval Inspections (NDA) |
106 |
174 |
174 |
Foreign Preapproval Inspections (ANDA) |
60 |
96 |
96 |
Foreign Bioresearch Monitoring Program Inspections |
61 |
91 |
91 |
Foreign Drug Processing (GMP) Program Inspections |
152 |
210 |
210 |
Foreign Adverse Drug Events Project Inspections |
8 |
26 |
26 |
Total Foreign FDA Inspections |
387 |
597 |
597 |
Import Field Exams/Tests |
4,587 |
3,500 |
4,000 |
Import Laboratory Samples Analyzed |
140 |
640 |
640 |
Import Physical Exam Subtotal |
4,727 |
4,140 |
4,640 |
Import Lines |
197,420 |
233,000 |
275,000 |
Percent Physical Exams of Import Lines |
2.4% |
1.77% |
1.69% |
PROGRAM OUTPUTS- |
FY 2003 |
FY 2004 |
FY 2005 |
---|---|---|---|
Bioresearch Monitoring Program Inspections |
127 |
140 |
160 |
Blood Bank Inspections |
1,375 |
1,159 |
1,180 |
Source Plasma Inspections |
278 |
228 |
240 |
Pre-Approval (Pre-Market) Program Inspections |
1 |
0 |
0 |
Pre-License Inspections |
14 |
8 |
15 |
GMP Inspections |
59 |
36 |
50 |
GMP (Device) Inspections |
14 |
51 |
51 |
Human Tissue Inspections |
227 |
343 |
463 |
Total Domestic Inspections |
2,095 |
1,965 |
2,159 |
PROGRAM OUTPUTS- |
|||
IMPORT/FOREIGN INSPECTIONS |
|||
Bioresearch Monitoring Program Inspections |
18 |
12 |
20 |
Blood Bank Inspections |
8 |
24 |
35 |
Source Plasma Inspections |
2 |
3 |
10 |
Pre-Approval (Pre-Market) Program Inspections |
1 |
0 |
0 |
Pre-License Inspections |
4 |
4 |
6 |
GMP Inspections |
20 |
14 |
25 |
GMP (Device) Inspections |
3 |
0 |
0 |
Total Foreign FDA Inspections |
56 |
57 |
96 |
Import Field Exams/Tests 1/ |
135 |
10 |
15 |
Import Lines |
26,596 |
31,000 |
37,000 |
Percent Physical Exams of Import Lines |
0.51% |
0.03% |
0.04% |
1/Includes MedWatch, Foreign reports and VAERs reports. |
PROGRAM OUTPUTS- |
FY 2003 |
FY 2004 |
FY 2005 |
---|---|---|---|
Preapproval /BIMO Inspections |
102 |
190 |
190 |
Drug Process and New ADF Program Inspections |
255 |
260 |
260 |
BSE Inspections |
2,598 |
2,800 |
3,720 |
Feed Contaminant Inspections |
57 |
100 |
100 |
Illegal Tissue Residue Program Inspections |
324 |
364 |
364 |
Feed Manufacturing Program Inspections |
457 |
300 |
300 |
State Contract Inspections: BSE |
3,119 |
3,100 |
5,600 |
State Contract Inspections: Feed Manufacturers |
412 |
360 |
360 |
State Contract Inspections: Illegal Tissue Residue |
407 |
670 |
670 |
State Partnership Inspections: BSE and Other |
700 |
700 |
700 |
Total FDA and State Contract Inspections |
8,431 |
8,844 |
12,264 |
State Contract Animal Drugs/Feeds Funding |
$1,650,000 |
$1,980,000 |
$5,000,000 |
Domestic Laboratory Samples Analyzed |
1,374 |
2,400 |
3,000 |
PROGRAM OUTPUTS- |
|||
IMPORT/FOREIGN INSPECTIONS |
|||
Foreign Preapproval/Bioresearch Monitoring Program Inspections |
30 |
50 |
50 |
Foreign Drug Processing and New ADF Program Inspections |
16 |
10 |
10 |
Total Foreign FDA Inspections |
46 |
60 |
60 |
Import Field Exams/Tests |
3,261 |
500 |
500 |
Import Laboratory Samples Analyzed |
388 |
775 |
775 |
Import Physical Exam Subtotal |
3,649 |
1,275 |
1,275 |
Import Lines |
146,360 |
173,000 |
204,000 |
Percent Physical Exams of Import Lines |
2.5% |
0.74% |
0.63% |
PROGRAM OUTPUTS- |
FY 2003 |
FY 2004 |
FY 2005 |
---|---|---|---|
Bioresearch Monitoring Program Inspections |
357 |
275 |
300 |
Inspections Pre-Approval |
146 |
125 |
150 |
GMP Inspections (Levels I, II, and III) |
1,680 |
1,680 |
1,680 |
Total Domestic Inspections: Non MQSA |
2,183 |
2,080 |
2,130 |
Inspections (MQSA) FDA Domestic (non-VHA) |
361 |
360 |
360 |
Inspections (MQSA) FDA Domestic (VHA) |
34 |
35 |
35 |
Inspections (MQSA) by State Contract |
7,804 |
7,700 |
7,700 |
Inspections (MQSA) by State non-Contract |
513 |
545 |
545 |
Total Domestic MQSA |
8,712 |
8,640 |
8,640 |
State Contract Devices Funding |
$1,140,000 |
$1,350,000 |
$1,350,000 |
State Contract Mammography Funding |
$9,114,000 |
$9,888,000 |
$9,888,000 |
Domestic Radiological Health Inspections |
129 |
200 |
200 |
Domestic Field Exams/Tests |
1,454 |
1,500 |
1,500 |
Domestic Laboratory Samples Analyzed |
146 |
310 |
310 |
PROGRAM OUTPUTS- |
|||
IMPORT/FOREIGN INSPECTIONS |
|||
Foreign Bioresearch Monitoring Inspections |
7 |
20 |
20 |
Foreign Preapproval Inspections |
45 |
60 |
60 |
Foreign GMP Inspections |
203 |
230 |
230 |
Foreign MQSA Inspections |
10 |
15 |
15 |
Foreign Radiological Health Inspections |
24 |
40 |
40 |
Total Foreign FDA Inspections |
289 |
365 |
365 |
Import Field Exams/Tests |
4,810 |
1,900 |
1,900 |
Import Laboratory Samples Analyzed |
1,397 |
1,680 |
1,680 |
Import Physical Exam Subtotal |
6,207 |
3,580 |
3,580 |
Import Lines |
2,236,983 |
2,600,000 |
3,100,000 |
Percent Physical Exams of Import Lines |
0.28% |
0.14% |
0.12% |